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ABSTRACT Conjugate vaccines protect vaccinated individ-
uals against both disease from and nasopharyngeal carriage of
Streptococcus pneumoniae and Haemophilus influenzae. Protection
is specific to the capsular serotype(s) included in the vaccine.
This specificity has raised concern that vaccination against
particular (‘‘targeted’’) serotypes may cause an increase in
carriage of (and diseases attributable to) nontargeted serotypes.
I analyzed a mathematical model designed to predict the factors
affecting, and the expected extent of, such replacement in the host
population. The conditions for competitive exclusion and coex-
istence of serotypes under mass vaccination are derived, and the
equilibrium carriage of target and nontarget serotypes is deter-
mined under various ecological and epidemiological conditions.
The eradication threshold for a target serotype in the presence
of competing, nontarget serotypes is always lower for serotype-
specific than for bivalent vaccines. In a two-serotype model, the
increase in the prevalence of any single nontargeted serotype due
to vaccination will not exceed the total reduction in prevalence of
a targeted serotype. However, if three or more serotypes interact
epidemiologically, vaccination against one type may increase
carriage of a second more than it decreases carriage of the first.
Carriage of a second serotype against which the vaccine offers
only partial protection may initially increase and then decrease
as a function of vaccine coverage. I discuss the extent to which
these theoretical results can account for existing data on serotype
replacement after vaccination against H. influenzae and their
implications for vaccine policy.
Polysaccharide–protein conjugate vaccines against Haemophi-
lus influenzae and Streptococcus pneumoniae protect individ-
uals against nasopharyngeal carriage of the targeted organisms
whereas older, polysaccharide vaccines protect against invasive
disease but apparently do not affect carriage (1). Protection
against carriage has been demonstrated for H. influenzae type
b (Hib) conjugate vaccines (2, 3) and (in more preliminary
studies) for multivalent pneumococcal vaccines (4–6). The
protection against carriage is specific to the capsular serotypes
included in these vaccines.
H. influenzae and S. pneumoniae are characterized by a carrier
state; most individuals who are nasopharyngeal carriers of these
organisms do not become ill (7, 8). Because nasopharyngeal
carriers are the main source of organisms transmitted to other
individuals, a vaccine that protects against carriage of targeted
serotypes will reduce the exposure of unvaccinated individuals to
colonized hosts (9). Such indirect protection, known as herd
immunity, has already been demonstrated in studies of conjugate
Hib vaccines (10, 11). In addition, population-wide reduction in
the carriage of particular serotypes of H. influenzae or S. pneu-
moniae may open ecological niches that will be filled by other
serotypes (6, 12–15). Such ‘‘serotype replacement’’ would be
likely to occur if the prevalence of bacterial serotypes and species
in nasopharyngeal carriage is regulated by competition from
other serotypes or species. Finally, if different serotypes compete
to colonize hosts, then vaccination against multiple serotypes, as
in the multivalent pneumococcal conjugate vaccines now being
tested, may have less than the anticipated herd immunity effect
against component serotypes. Multivalent vaccines might par-
tially compromise their effectiveness in reducing population
levels of carriage of each individual serotype by reducing the
levels of carriage of competing serotypes.
This paper analyzes a mathematical model for the epidemi-
ology of colonizing bacteria with multiple serotypes. It con-
siders two major questions: (i) When a serotype-specific
vaccine is introduced against one serotype, how much will the
prevalence of a competing serotype increase? and (ii) How
does the population-level effectiveness (herd immunity and
eradication threshold) of a multivalent vaccine depend on the
competition between targeted serotypes?
Before presenting the model, I briefly review the empirical
evidence bearing on these questions in H. influenzae and S.
pneumoniae.
Empirical Evidence. H. influenzae. Concerns about serotype
replacement have been raised several times with regard to the
conjugate vaccines against Hib (12–15). It has been reported that
some strains of Hib produce a bacteriocin active against non-b
serotypes of H. influenzae (16); bacteriocins may be a means of
excluding competing bacteria. Use of conjugate Hib vaccine in
developed countries has reduced carriage of Hib to almost zero
among vaccinated children from prevaccination levels ranging
around 5–10% (2, 3, 10, 11, 17, 18). Statistically discernible
increases in carriage of other H. influenzae serotypes have not
been detected (3, 10). There is some evidence that the incidence
of invasive disease from H. influenzae serotype f has increased
since the introduction of widespread Hib vaccination (19), but the
causes of this increase have not been identified.
S. pneumoniae. A recent report from The Gambia showed that
a pneumococcal conjugate vaccine reduced carriage of serotypes
included in the vaccine but increased carriage of other pneumo-
coccal serotypes (6). A multivalent pneumococcal conjugate
vaccine tested in Israel reduced carriage of vaccine serotypes, but
no increase was observed in nonvaccine serotypes (5). Several
lines of indirect, epidemiological evidence suggest that a popu-
lation of bacteria already established in the nasopharynx may
lower the probability of colonization by other organisms. Prior
antimicrobial use is a risk factor for carriage of drug-resistant
pneumococci (20, 21). One study specifically showed that anti-
microbial treatment was a risk factor for acquisition of a partic-
ular, drug-resistant strain, with a defined serotype (23F) and drug
resistance profile (21). This offers particularly strong evidence for
the role of competition because it excludes the possibility of
spontaneous emergence of resistance and suggests, instead, that
treatment increases the likelihood of colonization by a resistant
serotype. However, such studies do not demonstrate that it is
clearance of competing pneumococci, rather than clearance of
other bacteria, that increases the risk of colonization. Several
studies have shown antagonism between different species of
streptococci colonizing the nasopharynx (22). Studies of naso-
pharyngeal pneumococcal isolates from children in Papua New
Guinea (23–25) indicate that colonization with multiple serotypes
is less frequent than would be expected if each serotype circulated
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independently of the others. With one exception (23), however,
these studies sampled a small number of colonies and therefore
probably underestimated the number of serotypes carried. These
results are consistent with the hypothesis of interference but do
not rule out such plausible alternatives as geographic heteroge-
neity in transmission or serotype-specific differences in host
susceptibility to carriage.
Model. I analyzed a compartmental model (26) for the
dynamics of two serotypes of colonizing bacteria; the model’s
structure is shown in Fig. 1. The model assumes that suscep-
tible hosts enter the transmitting population at a constant rate,
L, and that hosts leave at a per capita rate u. In the absence
of vaccination, susceptible hosts (X) may be colonized with
either bacterial serotype 1 or 2, moving them into the carrier
compartments Y1 and Y2. Colonized hosts may be additionally
colonized with the other serotype, moving them into the
double carrier compartment Y12. These transitions occur ac-
cording to mass action processes, with susceptible hosts be-
coming colonized with serotypes 1 and 2 at rates b1X(Y1 1 Y12)
and b2X(Y2 1 Y12), respectively. Hosts already carrying a
particular serotype are less likely to acquire the other serotype;
this creates competition between the serotypes. Thus, hosts
already colonized with serotype 1 are colonized with serotype
2 at a rate c2b2Y1(Y2 1 Y12), and hosts colonized with serotype
2 are colonized with serotype 1 at a rate c1b1Y2(Y1 1 Y12). Here
0 # c1, c2 # 1, and the cs are the relative risk of acquiring a
serotype if already colonized with the other, compared with a
noncarrier; ci 5 0 corresponds to complete exclusion of dual
colonization, and ci 5 1 corresponds to complete indepen-
dence in the behavior of the two serotypes. Colonized hosts
lose each serotype independently and become susceptible to
colonization again at a rate g. Thus far, the model is very
similar to those of Dietz and Gupta et al. (27, 28).
To incorporate vaccination, the model further assumes that a
fraction f of all hosts initially enter a vaccinated, uncolonized class
(V) instead of the completely susceptible class; thus, the rates of
entry into the susceptible and vaccinated class are (1 2 f)L and
fL, respectively. f is termed the ‘‘vaccine coverage.’’ Vaccinated
hosts are completely protected against colonization with serotype
1 and protected completely, partially, or not at all against serotype
2. Vaccination only occurs for new entrants into the population;
therefore, we neglect the possibility that individuals can be
colonized before vaccination. The class of vaccinated carriers of
serotype 2 is denoted by W; vaccinated individuals acquire
serotype 2 at a rate kb2V(Y2 1 Y12 1 W); vaccinated individuals’
reduction in the rate of acquiring serotype 2 is termed the
‘‘vaccine efficacy against serotype 2’’ and is equal to 1 2 k.
Vaccinated hosts carrying serotype 2 are considered to be equally
infectious as unvaccinated ones; under this assumption, in the
presence of vaccination, the rates at which serotype 2 colonizes
susceptible hosts and carriers of serotype 1, respectively, are
b
2
X(Y2 1 Y12 1 W) and c2b2Y1(Y2 1 Y12 1 W). To simplify
calculations, define E1 [ Y1 1 Y12 and E2 [ Y2 1 Y12 1 W. In
addition, without loss of generality, set L 5 u 5 1; this corre-
sponds to an appropriate choice of temporal and spatial scale.
Then the model is:
dXydt 5 1 2 f 2 X~b1E1 1 b2E2!
1 g~2 2 f 2 E1 2 E2 2 2X 2 V! 2 X
dE1ydt 5 @b1X 1 c1b1~1 2 f 2 X 2 E1! 2 g 2 1#E1
dE2ydt 5 @b2X 1 c2b2~1 2 V 2 X 2 E2! 1 kb2V 2 g 2 1#E2 [1]
dVydt 5 f 2 kb2E2V 1 gW 2 V
dWydt 5 kb2E2V 2 ~1 1 g!W
It should be noted that the model makes no provision for
natural immunity to carriage arising from previous exposure.
See Discussion for consideration of this assumption.
RESULTS
Case 1. No vaccine. As in all models of this type, the
condition for a serotype to persist in the population, in the
absence of competing serotypes, is that its basic reproductive
number R0—the number of secondary hosts who acquire the
organism directly from one infectious host placed in an
unexposed population at equilibrium—must exceed 1 (26).
The basic reproductive number for serotype i is given in this
model by R0i 5 bi/(1 1 g). Two serotypes can coexist if each
has a basic reproductive number greater than 1 and each can
invade the population when the other is present at its equi-
librium (27, 28):
1y~1 2 c1 1 c1R02! ,
R01
R02
, 1 2 c2 1 c2R01. [2]
Case 2. Serotype-specific vaccine. When k 5 1, the model
describes competition between a target serotype, against which
vaccination is completely protective, and a nontarget serotype
against which vaccination offers no protection. This model is
a reasonable approximation to the effects of the Hib conjugate
vaccine (11). In this case, the conditions for coexistence with
coverage f are:
R01~1 2 f! . 1, R02 . 1,
and
1




, 1 2 c2 1 R01@f 1 c2~1 2 f!#;
[3]
as before, these are the conditions under which each serotype
can invade the equilibrium of the other alone.
The target serotype is eliminated when the vaccine coverage
exceeds a critical fraction fc given by:
fc 5 1 2
R02
R01@1 1 c1~R02 2 1!#
. [4]
(See Appendix for the derivation.)
This is less than the coverage required in the absence of a
competing serotype (in which case fc 5 1 2 1yR01); the
FIG. 1. Structure of the model, in which hosts can be carriers of either
or both of two serotypes of colonizing bacteria. Vaccination protects hosts
completely against carriage of serotype 1 (the ‘‘target’’ serotype) and
partially, fully, or not at all against carriage of a second serotype. Hosts
leave the population at a rate u per capita, shown by the unlabeled arrows.
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presence of the nontarget serotype works together with vac-
cination to reduce the transmission of the target serotype.
The critical coverage to eradicate serotype 1 increases with
serotype 1’s basic reproductive rate and decreases with the
basic reproductive number of serotype 2 and the degree to
which carriage of serotype 2 inhibits carriage of serotype 1. The
critical coverage does not depend on the inhibition of serotype
2 by serotype 1. Fig. 2 shows how this critical coverage depends
on R01, assuming strong competition between serotypes (c1 5
c2 5 0.2). The bottom most curve in each graph corresponds
to a completely serotype-specific vaccine (other solid curves
correspond to partially or completely bivalent vaccines, see
below). The dotted curve shows the critical coverage to
eliminate serotype 1 in the absence of competition. Particularly
for target serotypes with low basic reproductive numbers, the
contribution of competing serotypes can be considerable (e.g.,
reducing the critical coverage by over 50% if the two serotypes
have equal basic reproductive numbers and compete strongly).
Use of a serotype-specific vaccine will always increase the
carriage of a nontarget serotype that is inhibited by the target
serotype, as shown in Fig. 3. The magnitude of this increase
depends on various parameters, including the basic reproduc-
tive numbers of both serotypes, the vaccine coverage, and the
degree of competition between serotypes (c1 and c2). In Fig.
3a, a serotype that coexists with the target serotype in the
absence of vaccination increases in prevalence as the fraction
of the population vaccinated increases, until the target sero-
type is eliminated. Fig. 3b shows that vaccination with a
serotype-specific vaccine also can cause the appearance of a
new serotype that was outcompeted by the target serotype in
the absence of vaccination. This occurs if inequality 3 is
satisfied but inequality 2 is not.
A key prediction of this two-serotype model is that vacci-
nation will increase carriage of the nontarget serotype less than
it decreases carriage of the target serotype (this assertion is
justified in the Appendix). Stated another way, vaccination will
always decrease the total number of carriers. These phenom-
ena are illustrated in Fig. 3 a and b.
If more than two serotypes are present, however, this limitation
no longer applies. In a system comprised of three (or more)
serotypes, vaccination against one serotype may produce an
increase in the carriage of one or more other serotypes that is
greater than the reduction in carriage of the target serotype. This
may occur, for example, if before vaccination, the target serotype,
in combination with another, coexisting serotype (‘‘serotype 2’’),
competitively excludes a third serotype (‘‘serotype 3’’). If serotype
1 is eliminated by vaccination, and serotype 2 alone cannot
outcompete serotype 3, serotype 3 may achieve a prevalence
higher than the prevaccination prevalence of serotype 1. This
possibility is illustrated in Fig. 3c.
Case 3. Bivalent vaccine. Finally, we consider the case in
which a vaccine offers partial (0 , k , 1) or full (k 5 0)
protection against a second serotype. Such a model applies to
the multivalent pneumococcal conjugate vaccines currently
undergoing field trials. As above, we assume that the vaccine
gives 100% protection against carriage of the target serotype.
The condition for eliminating serotype 1 is given, as before,
by f . fc, but the expression for fc (given in the Appendix) is
more complicated. Fig. 2 shows how this threshold depends on
the basic reproductive number of the target serotype (x-axis)
and on the efficacy of the vaccine against the second serotype;
the upper curves correspond to increasing efficacy against
serotype 2. If the serotypes compete strongly, the threshold for
eliminating serotype 1 is considerably higher with a bivalent
vaccine than with a serotype-specific one.
Fig. 3 d–f shows the effects of vaccination with a bivalent
vaccine on the equilibrium prevalence of two serotypes. When
competition between serotypes is relatively weak, as in Fig. 3d (c1
5 c2 5 0.7), the effect of a bivalent vaccine on serotype 1 is similar
to the effect of a serotype-specific one (compare Fig. 3a), but the
bivalent vaccine also eliminates serotype 2. Fig. 3e shows that the
difference between bivalent and serotype-specific vaccines is
much greater when the serotypes compete strongly (c1 5 c2 5
0.1). The parameters for Fig. 3e match those of Fig. 3b, except that
the vaccine is highly effective against serotype 2 (k 5 0.1). This
prevents the appearance of serotype 2 (compare Fig. 3b) but
increases the critical coverage to eliminate serotype 1 consider-
ably, from '31% of the population in Fig. 3b to '55% in Fig. 3e.
Vaccination with a bivalent vaccine may increase carriage of a
type against which it has relatively low efficacy, and the preva-
lence of that serotype may change nonmonotonically with vaccine
coverage. In Fig. 3f, the prevalence of serotype 2 initially increases
with vaccine coverage, then declines. The increase in prevalence
occurs when the benefit to serotype 2 from reducing carriage of
serotype 1 outweighs the cost of partial vaccine-induced immu-
nity to serotype 2; once serotype 1 is eliminated, however, further
increases in vaccination rates reduce carriage of serotype 2.
In some cases, the goal of a bivalent vaccine is to reduce or
eliminate carriage of both serotypes. In eradicating two com-
peting serotypes, the critical coverage is just the larger of the
two critical coverages for each serotype in the absence of
competition:
f . max$1 2 1yR01, ~1 2 1yR02!y~1 2 k!%.




, 1 2 c2 1 R01@c2f 1 ~1 2 f!# and f , fc. [5]
Two serotypes that cannot coexist in the absence of a vaccine
will be unable to coexist in the presence of a vaccine that
protects completely against both of them; this can be seen by
noting that, for k 5 0, inequality 5 implies inequality 2 but not
vice-versa. With a partially protective vaccine, however, vac-
cination of a portion of the population can permit coexistence
of serotypes that otherwise could not coexist.
DISCUSSION
This paper has analyzed a mathematical model of the transmis-
sion dynamics of two or more serotypes of bacteria colonizing a
FIG. 2. Critical vaccination fraction fc required to eliminate sero-
type 1 as a function of serotype 1’s basic reproductive number R01
(x-axis) and degree of protection against serotype 2 (different curves).
The dashed curve shows the critical fraction if no competing serotype
was present, and the solid curves show the critical coverage for a
vaccine with 100% (top line, k 5 1) or partial (middle lines, k 5 0.7,
0.2) efficacy against serotype 2 and a vaccine specific to serotype 1
(bottom line, k 5 0). Parameters: R02 5 3, c1 5 0.2.
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population of hosts, with special attention to the effects of
vaccination against one or more serotypes. The model predicts
that serotype-specific vaccines will increase the prevalence of
serotypes excluded from the vaccine that compete with the
vaccine serotype. This increase may include the appearance of
novel serotypes that previously were unable to compete with the
target serotype. In a two-serotype system, the increase in carriage
of any one serotype will always be less than the decline in carriage
of the vaccine serotype; thus, in such a system, the total number
of individuals carrying neither serotype will always increase with
vaccination. In a system with three or more serotypes, however,
serotype-specific vaccination can increase the total fraction of
hosts carrying a nontargeted serotype more than it reduces the
fraction carrying the targeted serotype.
Competition from nontarget serotypes may be beneficial if
it reduces the fraction of hosts who must be vaccinated to
eliminate the target serotype. For this reason, elimination of
a target serotype by a vaccine effective against many other
serotypes (like the multivalent pneumococcal vaccines cur-
rently being tested) will require a higher level of coverage than
if a serotype-specific vaccine were used. If a vaccine is more
effective against one serotype than another, then carriage of
the second serotype may increase with vaccine coverage as
vaccination reduces carriage of the first, but then decline as
coverage increases, due to vaccine-induced protection against
the second serotype. Although the model is designed for
different serotypes of the same bacterial species, it may be
applied without modification to interspecific interactions (22).
Several studies of the effects of Hib conjugate vaccines have
failed to find any increase in carriage of nonvaccine serotypes
of H. influenzae among vaccine recipients, despite considerable
reductions in carriage of the b serotype (2, 3, 11). The
mathematical model suggests that the lack of replacement may
not generalize to other situations (different host populations
or different organisms) in which prevalence of targeted sero-
types is higher. In both Finland (3) and England (2, 10, 11),
where the studies were done, prevaccination carriage of Hib
was on the order of 4–7%. The model predicts that, even with
100% vaccine coverage of the population and maximum
competition between serotypes, the increase in carriage of any
other serotype would be at most equal to the prevaccination
prevalence of Hib. Such a small increase would be difficult to
detect amidst the temporal f luctuations in carriage of H.
influenzae reported in the Finnish study.
Thus, the lack of replacement by competing serotypes of H.
influenzae in developed countries may be a result of the low
rates of carriage of Hib. Carriage of both type b and non-b H.
influenzae is often considerably higher (29) in developing
countries. Pneumococcal carriage is much higher than Hib
carriage in developed countries (30). With higher prevalences
of targeted serotypes, even if the biological interactions be-
tween serotypes are identical to those in the British and
Finnish Hib studies, the number of hosts who acquire nontar-
geted serotypes may be considerably larger.
If replacement occurs, it will be more visible in studies of
vaccines in which treatment is randomized by whole commu-
nities rather than by individuals within a community. If only
the study subjects were vaccinated and these constituted a
small fraction of the transmitting population, the exposure of
vaccinees to each serotype circulating in the community would
change little; any increase in carriage of nonvaccine serotypes
by vaccinees would result only from changes in their own
FIG. 3. Fractions of the population carrying
serotype 1, serotype 2, both (1 and 2), or neither, at
equilibrium, under different coverage levels with a
vaccine specific to serotype 1 (a–c) or to serotypes
1 and 2 (d–f). Dual carriers are included in the rates
for serotypes 1 and 2. (a) With relatively weak
competition (c1 5 c2 5 0.7) and a strain 1-specific
vaccine, carriage of serotype 1 declines as vaccina-
tion levels increase while carriage of serotype 2
increases, but by less than the decline in serotype 1.
(b) With the same parameters, but stronger com-
petition (c1 5 c2 5 0.1), serotype 2 is excluded in the
absence of vaccination but appears as vaccination
rates increase, reducing serotype 1 carriage. Sero-
type 2 carriage levels increase until the fraction
vaccinated is large enough to eliminate serotype 1;
above that level, increased coverage has no effect on
serotype 2. Parameters for a and b: R01 5 2.2, R02
5 1.6, k 5 1. (c) In a three-serotype model with
vaccination against only serotype 1, a competing
serotype may increase in prevalence more than the
target serotype declines. Parameters: R01 5 4.0, R02
5 2.0; R03 5 3.2, cij (relative risk of acquiring
serotype i for a carrier of serotype j compared with
a host carrying no serotype) 5 0.1 for all i, j except
c21 5 0.9. Triple colonizations occur according to a
multiplicative model; all occur at a relative rate 0.01
except that hosts carrying serotypes 1 and 3 acquire
serotype 2 at relative rate 0.09. (d) A vaccine
offering 80% protection against serotype 2 (k 5 0.2)
and perfect protection against serotype 1 has results
similar to a serotype 1-specific vaccine if there is
weak competition between serotypes (compare a).
(e) When competition is stronger (c1 5 c2 5 0.1),
bivalent vaccines preclude replacement of serotype
1 by serotype 2 but increase the critical vaccination
threshold (compare b, same parameters but a sero-
type-specific vaccine). Parameters for d and e: R01 5
2.2, R02 5 1.6. (f) Carriage of serotype 2 can increase
until serotype 1 is eliminated, then decrease as a
function of increasing vaccination coverage. Param-
eters: c1 5 c2 5 0.1; k 5 0.8; R01 5 2.2, R02 5 1.8.
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susceptibility to carriage. This increase would be at most
'1y(1 2 prevaccination prevalence of the target serotype).
For example, if 500 people were vaccinated against Hib in a
large population (so that vaccination did not change the overall
carriage of Hib in the population), and carriage of Hib and
another serotype (e.g., H. influenzae type f) before vaccination
were 5 and 6%, respectively [as in the U.K. (10)], the expected
number of vaccinated H. influenzae type f carriers would be 32
(vs. 30 in 500 controls), assuming that the maximum possible
serotype replacement occurred. Such an increase would, of
course, be very difficult to measure. If this reasoning is correct,
then it will be much easier to see replacement (if it occurs) in
populations with high vaccine coverage than in studies of a
group of vaccinees in a mostly unvaccinated population.
Preliminary data on pneumococcal conjugate vaccines, al-
though consistently showing reduction of carriage of vaccine
serotypes (4–6), are split concerning the question of replacement
by competing serotypes, with clear evidence of replacement in
The Gambia (6) but no such evidence in an Israeli study (5).
Further studies will be needed to resolve this question empirically;
the model suggests that differences in the relative frequencies of
different serotypes in a population and the serotype composition
of the vaccine may account for different outcomes.
The model considered here describes the effects of vaccination
on carriage, not invasive disease. The relationship between car-
riage and disease for nasopharyngeal colonizers is complex, but
it is clear that, for most such bacteria, there are many more
carriers than victims of invasive disease (8, 25, 31). There is
considerable variation between serotypes in virulence, measured
as the probability that a colonized host will develop clinical
disease; for example, before the advent of vaccination, serotype
b accounted for '90% of capsulated isolates of H. influenzae-
causing disease in children (12, 19) but for a much smaller
percentage of isolates from asymptomatic carriers. Similar vari-
ation has been observed between serotypes of S. pneumoniae
(25). The model does not explicitly consider the complex rela-
tionship between immunity to carriage and immunity to invasive
disease. If a vaccine is highly efficacious against invasive disease
but less efficacious against carriage (as in the earlier generation
of polysaccharide vaccines), then the importance of carriage
levels will primarily be determined by residual disease in unvac-
cinated individuals. If vaccine-derived protection against invasive
disease is lower, then carriage of the vaccine-targeted serotype, if
it persists, will be manifest as invasive disease in both vaccinated
and unvaccinated persons.
Given such variation, one policy in designing vaccines would be
to include only the serotypes of a given species that cause the
majority of invasive disease. Such a policy might be expected to
produce the greatest reduction in disease, while maintaining the
additional benefits of competition from serotypes not included in
the vaccine. However, such vaccines may not remain effective in
the long run (32). The species of colonizing bacteria considered
here (as well as Neisseria meningitidis) are highly transformable,
and the association between capsular serotype and other genetic
characteristics, including virulence, may be short-lived (32–34),
especially in the presence of vaccine-induced selective pressure.
Vaccination cannot only change the prevalence of existing sero-
types but also permit the appearance of serotypes that were
previously absent. Such serotypes may or may not be virulent,
making their impact difficult to predict (41). These considerations
suggest that vaccines designed to ‘‘cover’’ serotypes that cause the
majority of invasive disease in the absence of vaccination may
require updating as the bacterial population shifts toward non-
target serotypes.
There is currently little evidence about the source or effects of
naturally acquired, specific immunity to colonization by these
bacteria. A role for serotype-specific immunity to colonization is
suggested by epidemiological evidence of an inverse correlation
between immunogenicity and acquisition rates of pneumococcal
serotypes (25) and by a study showing that exposure to polysac-
charide crossreactive with the H. influenzae type b capsule
protects against colonization with Hib (35). Immune responses
against antigens that are conserved across multiple serotypes
(such as the pneumococcal pneumolysin) also may offer some
protection against colonization (36), but it is not clear whether
such responses result from natural colonization. Sequential col-
onization of individuals by the same and different pneumococcal
serotypes (30) suggests that the efficacy of these immune re-
sponses is limited. If substantial crossreactive immunity to colo-
nization existed in the bacterial species considered here, it would
invalidate the important assumption of the model that the
presence of competing bacteria in the nasopharynx is the major
determinant of competition between serotypes.
The mathematical models in this paper are related to previous
models of multiple strain (or multiple serotype) pathogens. Most
directly relevant is McLean’s recent study (37), which showed that
vaccines could induce strain replacement in two models, one with
complete crossimmunity between strains and another that al-
lowed for the possibility of ‘‘superinfection’’ (38), in which one
strain replaces another within a host. Unlike the present model,
McLean’s model assumed that hosts became immune, rather than
susceptible again, upon termination of infection, and did not
allow for multiple simultaneous infection. Her assumptions,
which may be more appropriate for viral infections than for the
colonizing bacteria considered here, led to somewhat different
conclusions. Most notably, total prevalence could increase as a
result of vaccination in McLean’s two-serotype, superinfection
model. Several recent papers by May and Nowak have analyzed
superinfection (38, 39) and coinfection (40) (multiple simulta-
neous infection) for multiple-strain models and have shown that,
in a superinfection model, the effect of vaccination is to remove
the most virulent strains (39). The principal difference between
the present model and those of McLean, Nowak, and May is that
the present model, designed for bacteria that are usually carried
asymptomatically for a relatively long period, assumes that hosts
can carry multiple serotypes, and that competition between
serotypes is mediated by reduced colonization probabilities in a
host already colonized with another serotype. Previous models
attribute competition to cross-reactive host immunity derived
from previous infection with another strain (37) or to host death
induced by other, coinfecting strains (40). The superinfection
models have a similar mechanism of competition to the one
considered here but assume that each host can only carry one
strain; upon infection by a second strain, infection with the first
strain is terminated (38, 39). Two other models have described the
coexistence conditions for multistrain pathogens but have not
considered vaccination (27, 28).
The model assumes that the vaccine is completely protective
against carriage of the target serotype. This assumption is more
nearly correct for existing Hib vaccines (11) than for pneumo-
coccal vaccines (4). To a first approximation, less than perfect
efficacy might be accounted for by multiplying the fraction
vaccinated in the model by a factor equal to the vaccine efficacy.
A related assumption is that multiply colonized hosts are infec-
tious to the same degree, with each serotype, as hosts singly
colonized with either serotype. In multiply colonized hosts, the
proportions of different serotypes are often uneven (23); how-
ever, it is unlikely that this simplification will greatly change
model dynamics. Insofar as there are serotype-specific differences
in population size within a host, these should be reflected (both
in the model and in reality) as differences in the transmissibility
b. Finally, we have considered only equilibrium outcomes, not the
approach to these equilibria. Published estimates of prevalence,
acquisition rates, and loss rates for pneumococcal serotypes
suggest that unvaccinated populations are very close to their
expected equilibria (25).
Epidemiological studies to evaluate candidate pneumococ-
cal and Hib conjugate vaccines in both developed and devel-
oping countries offer an opportunity to test the predictions of
this model and to improve our understanding of the ecology of
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the nasopharyngeal bacteria. The model suggests tradeoffs
between the benefits of competition in eliminating serotypes of
particular concern and the risks of serotype replacement; these
tradeoffs should be considered in deciding the serotype com-
position of candidate vaccines. In addition, the model suggests
that optimism stemming from the lack of serotype replacement
following widespread Hib vaccination in developed countries
may not be warranted when considering other populations or
other bacterial species.
APPENDIX
Proof that the Increase in the Nontarget Serotype Will Be
Less Than the Decrease in the Target Serotype in the Two-
Serotype Model. For ease of calculation, we assume that 100%
of the population is vaccinated and that the vaccine gives no
protection against the nontarget serotype (these assumptions
are conservative because they maximize the fraction of the
population infected with the nontarget serotype at the vacci-
nated equilibrium). We want to show that
DE2 5 Wvacc 2 E2unvacc , E1unvacc. [A1]
The density of uninfected hosts is given by Vvacc 5 1yR02.
Before vaccination, the number of hosts carrying neither
serotype (noncarriers) is given by Xunvacc 5 1yR02 2 c2Y1unvacc.
Clearly, Vvacc . Xunvacc. Using the definitions in the model
section above, this implies:
1 2 Vvacc 5 Wvacc , 1 2 Xunvacc
5 Y1unvacc 1 E2unvacc , E1unvacc 1 E2unvacc.
This is equivalent to (Eq. A1), q.e.d.
Critical Fraction to Vaccinate. The critical fraction that
must be vaccinated to eliminate serotype 1 is that value of f that
makes the realized reproductive rate of serotype 1 equal to
unity. This is given by the equation:
R01~S˜~fc! 1 Y˜2~fc!! 5 1, [A2]
where S˜(fc) and Y˜2(fc) are the densities of unvaccinated,
noncarrier hosts and unvaccinated carriers of serotype 2,
respectively, as calculated at equilibrium in the absence of
serotype 1 with vaccine coverage fc.
If the vaccine gives no protection against serotype 2 (k 5 1),
then, using (Eq. A2),
fc 5 1 2
R02
R01@1 1 c1~R02 2 1!#
.
If the vaccine gives partial protection against serotype 2 and if
serotype 1 can coexist in the presence of serotype 2 without
vaccination, then (again, using Eq. A2), the critical coverage
to eliminate serotype 1 is given by:
fc 5 minS1 2 B 2 CÎD2A , 1 2 1yR01D ,
where: A 5 c1
2(1 2 k)R01R02; B 5 R01(k 2 c1)(1 2 c1) 1
2R02c1(1 2 k) 1 R01R02c1k(1 2 c1); C 5 (1 2 c1); and D 5
R01[R01(c1 2 k)2 1 4R02c1k(1 2 k) 1 c1kR01R02(2k 2 2c1 1
c1kR02)].
The quadratic form applies if serotype 2 is present when
serotype 1 is eradicated; the simpler form of 1–1yR01 applies
if serotype 2 is not present.
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